Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2387-2392

  Bohjanen, Paul R ^a   Johnson, Melissa D ^a   Szczech, Lynda A ^a   Wray, Dannah W ^a   Petros, William P ^a   Miller, Cameron R ^a   Hicks, Charles B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; MATHEMATICAL MODEL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; STEADY STATE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FEMALE; HALF LIFE TIME; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMAN; KIDNEY FAILURE, CHRONIC; LAMIVUDINE; MALE; MIDDLE AGE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; RENAL DIALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS; MIDDLE AGED;

EID: 0035991716     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2387-2392.2002     Document Type: Article

References (27)

1. The clinical spectrum of renal disease associated with human immunodeficiency virus
2. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults
3. + cells per cubic millimeter
4. Renal disease in patients with AIDS: A clinicopathologic study
5. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
6. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
7. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction
8. Renal complications in patients with the acquired immune deficiency syndrome (AIDS)
9. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy
10. Crescentic IgA nephropathy as a manifestation of human immune deficiency virus infection
11. Clinical pharmacokinetics of lamivudine
12. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis
13. Captopril and renal survival in patients with human immunodeficiency virus nephropathy
14. Brief report: Idiotypic IgA nephropathy in patients with human immunodeficiency virus infection
15. HIV-associated immune-mediated renal disease
16. Nephropathy associated with infection by human immunodeficiency virus: A report on 11 cases including 6 treated with zidovudine
17. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1
18. Glomerular lesions in the acquired immunodeficiency syndrome
19. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection
20. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection
21. Renal involvement in the acquired immunodeficiency syndrome: Presentation, clinical course, and therapy
22. Renal complications in HIV disease
23. The types of renal disease in the acquired immunodeficiency syndrome
24. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus
25. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase I/II study
26. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy